Myasthenia gravis and IVIG (intravenous immunoglobulin)

For clinicians, IVIG occupies a clear niche in the modern management of myasthenia gravis. When a patient presents with an acute exacerbation—particularly with bulbar or respiratory compromise—rapid immunomodulation is required while symptomatic agents and maintenance immunotherapies are adjusted. High‑dose IVIG provides a prompt, temporary reduction in pathogenic IgG activity. Mechanistically, pooled immunoglobulin exerts anti‑idiotypic effects, saturates Fc‑mediated recycling pathways that prolong autoantibody survival, down‑regulates activating Fc receptors, and inhibits complement deposition at the neuromuscular junction. The net result is a clinically meaningful improvement in strength, often beginning within several days and persisting for several weeks. Randomized trials and systematic reviews support this short‑term benefit. In head‑to‑head comparisons, plasma exchange (PLEX) often achieves improvement slightly faster, but at the cost of invasiveness, central access, and hemodynamic considerations; IVIG offers comparable functional gains with easier logistics in many centers. Consensus guidelines therefore endorse either IVIG or PLEX for crisis/exacerbation, with choice tailored to urgency, vascular access, comorbidities, and local expertise. By contrast, long‑term maintenance IVIG is generally not first‑line. The evidence base for sustained disease control with periodic infusions is limited, and the therapy carries cumulative costs, infusion burden, and recognized risks including thromboembolism, hemolysis, aseptic meningitis, and kidney injury—particularly in patients with vascular or renal risk profiles. Nevertheless, maintenance IVIG or subcutaneous immunoglobulin can be considered in refractory cases or when conventional steroid‑sparing agents (e.g., azathioprine, mycophenolate) and biologics are contraindicated or ineffective. The therapeutic landscape is rapidly evolving. Complement inhibitors (eculizumab/ravulizumab) and neonatal Fc receptor (FcRn) blockers (efgartigimod/rozanolixizumab) provide targeted options for refractory AChR‑positive MG and may reduce reliance on recurrent IVIG in some patients. Phenotyping matters: MuSK‑positive MG often responds better to PLEX and B‑cell–directed approaches (e.g., rituximab). Safety practice emphasizes pre‑infusion assessment (renal function, thrombotic risk, product selection), careful infusion protocols, and post‑infusion monitoring for hemolysis or aseptic meningitis. Access considerations—payer authorization, site‑of‑care policies, and product availability—also influence real‑world selection and timing of IVIG.

Traditional and integrative perspectives approach MG through the lens of systemic balance and vitality. In Traditional Chinese Medicine, MG‑like presentations correspond to Wei Zheng, often attributed to Spleen and Kidney Qi deficiency complicated by phlegm‑damp obstruction. Treatment principles emphasize tonifying Qi, supporting yang where appropriate, and resolving phlegm to restore neuromuscular function. Herbal formulas—frequently including qi‑tonics such as Astragalus (Huangqi)—and acupuncture protocols targeting fatigue and bulbar symptoms are used with the intent to strengthen foundational reserves and modulate immune reactivity. Small clinical studies and case series report improvements in fatigue and quality of life, though methodological limitations and heterogeneity constrain firm conclusions. Ayurveda frames fluctuating weakness and fatigability as Vata predominance with depleted ojas (vital essence). Gentle Rasayana strategies—nutritive herbs like Withania somnifera (Ashwagandha), restorative diet, and pranayama—are employed to bolster resilience. These modalities are typically introduced gradually and adapted to the patient’s energy envelope, with close attention to interactions with conventional medications. From an integrative standpoint, crisis management remains firmly biomedical: IVIG or plasma exchange, airway protection, and guideline‑directed immunotherapy are central. Traditional therapies are considered adjuncts aimed at symptom relief, stress reduction, and recovery between exacerbations. Collaboration is key—practitioners coordinate with neurology teams to avoid interactions (for example, caution with cholinergic or sedative herbs) and to tailor non‑pharmacologic supports like acupuncture, qigong, or yoga for breathing and fatigue. While the evidentiary foundation for these adjuncts is emerging rather than definitive, many patients value them for holistic support, provided safety and communication are prioritized.